CEL SCI CORP

CEL SCI Corp.

Biotechnology • Healthcare • Vienna, VA, United States • CVM (ASE)

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

703 506 9460 8229 Boone Boulevard, Vienna, VA 22182, United States

Stock Performance (90 Days)

Data through Dec 30, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Why CEL SCI Corporation stock is considered a top pick - Value Traps to Avoid & Affordable Investment Portfolio - bollywoodhelpline.com
bollywoodhelpline.com • Dec 26
Cel-Sci CEO Makes Bold Stock Purchase! - TipRanks
TipRanks • Dec 5
CEL-SCI stock falls after pricing $10M public offering at discount - Investing.com
Investing.com • Aug 28
CEL-SCI Corp. Prices Public Offering Of 1.11 Mln Shares At $9.00/shr - Nasdaq
Nasdaq • Aug 27
Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine - Stocktwits
Stocktwits • Oct 15

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has CEL SCI CORP had layoffs?
No layoff events have been recorded for CEL SCI CORP in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
What industry is CEL SCI CORP in?
CEL SCI CORP operates in the Biotechnology industry, within the Healthcare sector.
Is CEL SCI CORP a publicly traded company?
Yes, CEL SCI CORP is publicly traded under the ticker symbol CVM on the ASE. The company has a market capitalization of approximately $0.04 billion.
Where is CEL SCI CORP headquartered?
CEL SCI CORP is headquartered in Vienna, VA, United States at 8229 Boone Boulevard, Vienna, VA 22182, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.